Apply to trial NCT05654506

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening